Search

Home > News & Events > Current News

Current News

Current SATVI news

26 April 2019 New Vacancies added
Fri, 26 Apr 2019 - 13:30

SATVI invites applications to several positions at its Worcester field site office.  

 

16 April 2019 Latest Research: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study
Wed, 17 Apr 2019 - 08:15

SATVI authors Drs. Adam Penn-Nicholson, Stanley Kimbung Mbandi, Michelle Fisher, Professors Mark Hatherill and Tom Scriba have co-authored a paper titled "Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study" appearing in the Plos Medicine journal. 

14 April 2019 SATVI wins Social Responsiveness Award
Sun, 14 Apr 2019 - 19:45

University of Cape Vice Chancellor, Professor Mamokgethi Phakeng announced the South African Tuberculosis Vaccine Initiative (SATVI) as the winner of the 2018 Vice Chancellor Social Responsiveness Award during the April 2019 Health Faculty Sciences graduation. 

25 March 2019 World TB Day 3 Peaks Challenge
Mon, 25 Mar 2019 - 21:00

For World TB Day 2019 (24 March 2019) the South African Tuberculosis Vaccine Initiative (SATVI) team tackled the World TB Day Three Peaks Challenge which entailed ascending up Devils Peak, Platteklip Gorge and Lions Head in one day, in a bid to raise awareness about Tuberculosis. 

6 March 2019 Latest Research: A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates
Tue, 05 Mar 2019 - 20:15

SATVI researchers Miguel Rodo, Professor Tom Scriba, Drs. Virginie Rozot, Elisa Nemes and Profesor Mark Hatherill have published a article titled: "A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates" appearing in the PLoS Pathogens journal.

4 March 2019: 2018 Annual Report Now Available
Tue, 05 Mar 2019 - 18:45

The South African Tuberculosis Vaccine Initiative 2018 Annual Report is now available. 

19 January 2019 Research Published: Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria
Mon, 04 Feb 2019 - 15:00

SATVI Authors Professors Mark Hatherill, Tom Scriba, Dr Munyaradzi Musvosvi, Humphrey Mulenga, Ashley Veldsman have co-authored a research paper titled "Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria" appearing in the PLos One Journal.

17 January 2019 Research Published: Batf2 differentially regulates tissue immunopathology in Type 1 and 2 diseases
Mon, 04 Feb 2019 - 14:30

Professor Tom Scriba and Dr Adam Penn-Nicholson have co-authored a research publication titled: "Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases" appearing in the Mucosal Immunology Journal.

11 December 2018 Research Published Building capacity for advances in TB research
Tue, 11 Dec 2018 - 14:30

Professor Mark Hatherill has co-authored a journal article titled "Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting" appearing in the Tuberculosis (Edinb) Journal.

6 December 2018 Research Published: Metabolite changes in blood predict the onset of TB
Fri, 07 Dec 2018 - 14:00

Professor Tom Scriba has co-authored a paper titled: “Metabolite changes in blood predict the onset of tuberculosis” in the  Nature Journal.

1 December 2018 Research Published: Safety and Immunogenicity of early Bacillus Calmette-Guerin (BCG) vaccination in infants who are preterm and/or have low birth weights:
Tue, 04 Dec 2018 - 14:00

Prof Mark Hatherill has co-authored a journal article titled: "Safety and Immunogenicity of early Bacillus Calmette-Guerin (BCG) vaccination in infants who are preterm and/or have low birth weights: A systematic review and meta-analysis" appearing in the Journal of American Medical Association (JAMA).

15 November 2018 Research: Commentary WHO Preferred Product Preferences for TB Vaccines
Thu, 15 Nov 2018 - 11:30

SATVI Director Professor Mark Hatherill has co-authored a commentary titled "WHO preferred product characteristics for new vaccines against tuberculosis" appearing in The Lancet journal.

Pages